High Court Won't Eye Risperdal Verdict Against J&J Unit

Law360, New York (January 11, 2016, 1:52 PM EST) -- The U.S. Supreme Court on Monday declined to review the South Carolina Supreme Court’s $124 million judgment — originally a $327 million jury verdict — against a Johnson & Johnson subsidiary in the state's suit over deceptive marketing of the antipsychotic Risperdal.

As is customary, the high court didn’t comment on the petition for a writ of certiorari by Ortho-McNeil-Janssen Pharmaceuticals Inc., which had argued that the state Supreme Court’s nine-figure penalty was unconstitutional because there was no showing of actual injury or harm.

“Indeed, the South Carolina Supreme Court readily acknowledged that Janssen’s conduct ‘likely had little impact on the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS